AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for debilitating medical conditions. Their primary therapeutic areas of interest include neurology and gastroenterology. AEON aims to address significant unmet medical needs by leveraging its expertise in neurotoxin development and clinical execution. The company went public via a SPAC merger with Alpha Healthcare Acquisition Corp. III in July 2023.
The Irvine headquarters serves as the central nexus for AEON Biopharma's corporate strategy, research and development coordination, clinical trial management, and administrative operations.
Located in a modern business park, the facility is designed to support the operational needs of a clinical-stage biopharmaceutical company, likely featuring contemporary office spaces and meeting facilities conducive to collaboration.
The work culture at AEON Biopharma likely emphasizes innovation, scientific rigor, patient-centricity, and a collaborative approach to drug development, driven by the goal of bringing novel treatments to market.
As the primary corporate office, the Irvine headquarters is crucial for overseeing all aspects of the company's pipeline development, investor relations, and strategic partnerships.
AEON Biopharma is primarily U.S.-based with its headquarters in California. While its direct office presence is concentrated in the U.S., its clinical development programs for ABP-450 may involve collaboration with clinical research organizations (CROs) and trial sites internationally to support global drug development and future market access.
9800 Muirlands Blvd, Suite C
Irvine
CA
USA
Address: Previous mailing/investor relations address, may not be a full operational office. Specific street address for this secondary location is not consistently publicized as a primary operational site.
Potentially served administrative or financial communication purposes prior to or during the consolidation of operations at the current Irvine headquarters. Current significance as a distinct operational office is minimal.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AEON Global Health' leadership includes:
AEON Global Health has been backed by several prominent investors over the years, including:
Following its SPAC merger in July 2023, AEON Biopharma solidified its executive team. Key appointments include Chris Carr as COO & GC and Alex Wilson as SVP, Finance, reflecting the company's transition to a public entity and its focus on advancing clinical programs. No high-profile executive departures have been noted in the immediate past 12 months.
Discover the tools AEON Global Health uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AEON Biopharma, Inc. likely uses a common corporate email format, typically combining the employee's first initial and last name, or first name.last name, with the company domain.
[first_initial][last]@aeonbiopharma.com
Format
mforth@aeonbiopharma.com
Example
80%
Success rate
GlobeNewswire • May 8, 2024
AEON Biopharma announced its Q1 2024 financial results, detailing progress in its ABP-450 clinical programs for cervical dystonia and chronic migraine. The company highlighted upcoming data readouts and milestones for its therapeutic candidates....more
GlobeNewswire • March 6, 2024
AEON Biopharma announced plans to present clinical data and program updates for ABP-450 at several prestigious medical conferences, focusing on its applications in treating cervical dystonia and episodic/chronic migraine....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AEON Global Health, are just a search away.